NCT07662850 Effects of Blood Flow Restriction Training and Instrument-Assisted Soft Tissue Mobilization for Pain, Strength, Range of Motion, and Kinesiophobia Among ACL Reconstruction Patients.
| NCT ID | NCT07662850 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Lahore University of Biological and Applied Sciences |
| Condition | ACL Reconstruction |
| Study Type | INTERVENTIONAL |
| Enrollment | 46 participants |
| Start Date | 2026-07-28 |
| Primary Completion | 2026-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 46 participants in total. It began in 2026-07-28 with a primary completion date of 2026-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized clinical trial aims to compare the effects of Blood Flow Restriction Training (BFR) and Instrument-Assisted Soft Tissue Mobilization (IASTM) on pain, quadriceps muscle strength, knee range of motion (ROM), and kinesiophobia in patients following anterior cruciate ligament reconstruction (ACLR). ACLR patients commonly experience persistent muscle weakness, limited ROM, pain, and fear of movement, which can delay functional recovery and return to activity. A total of 46 participants (8-16 weeks post-ACLR) will be randomly allocated into two groups: a BFR group and an IASTM group. Both groups will receive interventions twice weekly for 8 weeks alongside standard physiotherapy. The BFR group will perform low-load resistance exercises under controlled vascular occlusion, while the IASTM group will receive soft tissue mobilization using specialized instruments combined with conventional rehabilitation. Outcome measures will include quadriceps strength (handheld dynamometer), pain (Numeric Pain Rating Scale), knee ROM (goniometer), and kinesiophobia (Tampa Scale of Kinesiophobia), assessed at baseline and post-intervention. The study aims to determine which intervention provides superior improvements in physical and psychological outcomes during early rehabilitation after ACL reconstruction.
Eligibility Criteria
Inclusion Criteria: * Age between 18 and 40 years. * Both genders. * Undergoing Primary Unilateral ACLR (using autologous tendon graft). * Medically cleared for low load rehabilitation (Wound healed, stable graft per surgeon). * Active knee flexion of ≥100° on the operative limb. * 8-16 weeks after reconstructive surgery. * Willing to comply with all rehabilitation sessions and follow up assessments; give informed consent Exclusion Criteria: * Significant meniscectomy requiring protected weight-bearing * Active DVT, vascular disease, uncontrolled hypertension or other BFR contraindications * Patients exhibiting extension lag (inability to achieve full active knee extension) on the operated limb. * Neuromuscular disorders * Skin lesions preventing IASTM * Pregnancy * Contraindications to exercise
Contact & Investigator
Dr Shaoib Waqas, Phd
STUDY DIRECTOR
Lahore University of Biological and Applied Sciences
Frequently Asked Questions
Who can join the NCT07662850 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 40 Years, studying ACL Reconstruction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07662850 currently recruiting?
Yes, NCT07662850 is actively recruiting participants. Contact the research team at shoaib.waqas@ubas.edu.pk for enrollment information.
Where is the NCT07662850 trial being conducted?
This trial is being conducted at Lahore, Pakistan.
Who is sponsoring the NCT07662850 clinical trial?
NCT07662850 is sponsored by Lahore University of Biological and Applied Sciences. The principal investigator is Dr Shaoib Waqas, Phd at Lahore University of Biological and Applied Sciences. The trial plans to enroll 46 participants.